Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMB071703 in Advanced Solid Tumors
NCT06292858Phase 1Recruiting
- Sponsor
- Immunoah Therapeutics, Inc.
- Start
- Feb 2023
- Primary completion
- Apr 2025
- Modality
- IgG Antibodies, Bispecific Antibodies, Anti-inflammatory mAbs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMB071703 in solid tumor (advanced stage), sponsored by Immunoah Therapeutics, Inc. Primary endpoints: Incidence of adverse events/serious adverse event related with IMB071703 injection, Dose-limiting toxicity and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
IMB071703
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06292858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06292858.